Overall , intervention groups obtained higher 25(OH)D concentration than controls and there was obvious dose – response effect between intake dose and 25(OH)D concentration .
Baseline 25(OH)D concentration and age were significant indicators for 25(OH)D concentration .
Conclusions Regional- and age-specific recommended dosages of VitD supplements for population to achieve optimal 25(OH)D concentrations have been suggested
Background / Objectives Optimal doses of vitamin D ( VitD ) supplement in different population s are unclear .
We aim to evaluate the relationship between VitD supplementation and post-intervention serum 25-hydroxyvitamin D [ 25(OH)D ] concentration , to provide a recommended dosage of VitD for achieving an optimal 25(OH)D concentration for different population s .
Vitamin D Supplementation and Hemoglobin Levels in Hypertensive Patients: A Randomized Controlled Trial
Epidemiological evidence suggests that circulating 25-hydroxyvitamin D ( 25OHD ) levels are inversely associated with hemoglobin ( Hb ) levels and anemia risk . We evaluated whether vitamin D supplementation improves Hb levels and reduces anemia risk in hypertensive patients . Two hundred patients with 25OHD levels < 75 nmol/L who attended the Styrian Vitamin D Hypertension Trial were included , of whom 188 completed the trial . Patients r and omly received 2800 IU vitamin D3 daily or a matching placebo for eight weeks . Initially , the prevalence of anemic status ( Hb levels < 12.5 g/dL ) and deficient 25OHD levels ( < 30 nmol/L ) was 6.5 % and 7.5 % , respectively . All anemic patients had 25OHD levels > 50 nmol/L. The mean ( 95 % confidence interval ) vitamin D effect on Hb levels was 0.04 ( −0.14 to 0.22 ) g/dL ( P = 0.661 ) . Moreover , vitamin D treatment did not influence anemic status significantly ( P > 0.999 ) . Likewise , vitamin D had no significant effect on Hb levels in the subgroups of anemic patients or in patients with initial 25OHD levels < 30 nmol/L. In conclusion , a daily vitamin D supplement of 2800 IU for eight weeks did not improve Hb levels or anemic status  in hypertensive patients . Future trials should focus on anemic patients with deficient 25OHD levels ( e.g. , < 30 nmol/L ) . This trial is registered with clinical trials.gov [ NCT02136771 ]
Overall , intervention groups obtained higher 25(OH)D concentration than controls and there was obvious dose – response effect between intake dose and 25(OH)D concentration .
Baseline 25(OH)D concentration and age were significant indicators for 25(OH)D concentration .
Conclusions Regional- and age-specific recommended dosages of VitD supplements for population to achieve optimal 25(OH)D concentrations have been suggested
Background / Objectives Optimal doses of vitamin D ( VitD ) supplement in different population s are unclear .
We aim to evaluate the relationship between VitD supplementation and post-intervention serum 25-hydroxyvitamin D [ 25(OH)D ] concentration , to provide a recommended dosage of VitD for achieving an optimal 25(OH)D concentration for different population s .